Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.

Slides:

Advertisements

Similar presentations

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Advertisements

Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.

A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)

Introduction Discussion CT abdomen 3/3/06 lightheadedness and watery diarrhea. TSH was again less than 0.01, and ACTH less than 5. AST and ALT were 240.

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

LMS-02 A phase II single-arm multicenter study of Trabectedin in combination with Doxorubicin as first-line treatment of metastatic and/or locally advanced.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.

A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma Coordinating Investigator:

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Targeting Tumors Using Endogenous Albumin

Optimizing the use of trabectedin in the daily clinical practice in ASTS Axel Le Cesne, MD.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

Clinical Case Nº3 Dr. Markus Schuler. Case description 58-year-old man History of severe cardiac problems Large tumour in the left thigh Tests results:

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

Systemic therapy More recent agents: Unregistered agents:

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

CLINICAL PRACTICE GUIDELINES Connective Tissue Oncology Society 2005 Meeting, Boca Raton Vivien Bramwell Chair, NCIC-CTG Sarcoma Committee Canadian Sarcoma.

Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,

A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma Nabeel Pervaiz Nigel.

HCI Sarcoma Services Sequential Dependency of Radiotherapy for Soft-Tissue Sarcoma S Sampath TE Schultheiss YJ Hitchcock RL Randall DC Shrieve JYC Wong.

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

Clinical Case Nº1 Dr. Giovanni Grignani. Patient medical history (I) 53-year-old woman Mild form of anxiety-depression treated with paroxetine 20 mg per.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

Estimating the population-based incidence for sarcoma and GIST in three European regions G. Mastrangelo University of Padova.

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

Per-Ulf Tunn, D. Andreou, S. Fehlberg, M. Werner, P. Reichardt

13 years of trabectedin and 5 years of Yondelis® in STS: what have we learnt? Le Cesne Axel, CTOS 2012, Prague.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:

Prognostic value of myogenic differentiation in adult soft tissue sarcomas (STS) A study of 855 cases from the French Sarcoma Group N Stock, MC Chateau,

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

MEASURING CLINICAL EFFICACY IN PHASE II TRIALS Response: Karnofsky, WHO, RECIST Event rate: progression free/survival Time to event: progression/survival.

Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.

Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.

Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.

EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.

Nabhan C et al. Proc ICML 2013;Abstract 102.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Pt ZJ 19yo M that presented to Seattle Children’s for evaluation of 3 lesions found on recent PET CT ◦ One large mass in the posterior mediastinum just.

Surgical Management of Pulmonary Metastases in Pediatric Patients with Ewing Sarcoma Kevin Hug.

12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.

Biology of Sarcomas “The first thing that the general medical oncologist has to realize is that the parallel word to sarcoma is actually carcinoma,

Figure #1 Overall survival Figure #2 Disease free survival

Advanced Soft Tissue Sarcoma: Current and Future

What's on the Horizon for Soft Tissue Sarcoma?

HISTOLOGY-SPECIFIC NOMOGRAM FOR PATIENTS AFFECTED BY PRIMARY RSTS

CUP is a clinico-pathological syndrome of many specific cancer

Presentation transcript:

Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg

1 Taxonomy of soft tissue sarcoma Taylor et al., Nat Rev Oncology 2011 HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-BrandenburgP. Reichardt

2 Synovial sarcoma Synovial sarcoma accounts for approximately 8% of all soft tissue sarcomas. Higher incidence in adolescents and young adults (>50% between 10 and 40 years). HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-BrandenburgP. Reichardt

3 Distribution of histological subtypes Distribution of histological types: % of all sarcomas diagnosed in 3 European regions (Aquitaine and Rhône-Alpes in France, Veneto in Italy; ): Mastrangelo G, et al. Cancer Apr 19. doi: /cncr HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-BrandenburgP. Reichardt

4 HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg Individual sarcoma histologies as proportion of all soft tissue sarcoma (STS) by age according to Surveillance, Epidemiology and EndResults (SEER) data, Parham et al. ASCO 2011

5 Synovial sarcoma Synovial sarcoma accounts for approximately 8% of all soft tissue sarcomas. Higher incidence in adolescents and young adults (>50% between 10 and 40 years). Typically affects the extremities (70%), case reports in multiple primary sites. Displays a variable degree of epithelial differentiation. Specific chromosomal translocation t(X;18)(p11;q11) that leads to formation of a SS18-SSX fusion gene. HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-BrandenburgP. Reichardt

6 Synovial sarcoma - Ifosfamide P. ReichardtHELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg

7 Synovial sarcoma – Combination chemotherapy P. ReichardtHELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg

8 Synovial sarcoma – Combination chemotherapy P. ReichardtHELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg

9 Synovial sarcoma - Gefitinib P. ReichardtHELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg

10 Synovial sarcoma: Options after doxo/ifo Trabectedin: Retrospective pooled analysis including 45 SS patients: In other retrospective analysis of 61 SS patients, trabectedin showed an activity similar to that in leiomyosarcoma and liposarcoma, with a significant percentage of patients experiencing prolonged disease control (25% of cases therapy was continued for ≥5 m; Clinical benefit rate: 50%). Median PFS was 3.0 months and 6-month PFS rate of 22%. Median OS was 13.9 months, with 2 years survival rate of 28%. Median OS Synovial: 13,9 months Le Cesne A, et al. Eur J Cancer. 2012;48(16): ; Sanfilippo R, et al. J Clin Oncol. 2010;28(Suppl15):712 HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-BrandenburgP. Reichardt

11 In the pazopanib registration study, 38 synovial sarcoma patients were included: Synovial sarcoma: Options after doxo/ifo Deeks E, et al. Drugs. 2012;72(16): ; FDA Review NDA /S-010 Votrient ® (pazopanib) Pazopanib significantly prolonged progression-free survival over placebo in this population (4.1 vs 1,0 months; HR=0.39). However, there was a lower survival with pazopanib vs placebo (8.7 vs 21.6 months) for this subtype. HELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-BrandenburgP. Reichardt

12 Synovial sarcoma – adjuvant therapy P. ReichardtHELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg SS seems to be a subtype which benefits from adjuvant chemotherapy: -In a retrospective analysis of 271 SS patients, among patients with macroscopically resected disease, those who received adjuvant chemotherapy had more favorable outcomes than those who did not receive chemotherapy (5-year MFS 60 vs. 48%). Ferrari A, et al. Cancer. 2004;101(3):627-34

13 P. ReichardtHELIOS KLinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg Le Cesne et al., ASCO 2008, #10525 Synovial sarcoma – adjuvant therapy (EORTC Meta-analysis)